Clinical trials: Endocrine System Disorder
Postherpetic Neuralgia, Diabetic Neuropathy
A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions
Patients with postherpetic neuralgia (PHN), diabetic neuropathy (DN), complex regional pain syndrome (CRPS), carpal tunnel syndrome, HIV neuropathy, idiopathic sensory neuropathy, or other peripheral neuropathy participated in a…
- Conditions
- Postherpetic Neuralgia, Diabetic Neuropathy, Complex Regional Pain Syndrome, Carpal Tunnel Syndrome
- Trial name
- NCT00904202
- Testing
- Gabapentin + Lidoderm®
- Where
- 7 sites in United States
- Volunteers
- 62 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Platinum Sensitive, BRCA Mutated
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
A Phase III, randomised, double-blind, placebo-controlled, multi-centre study to assess the efficacy of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with…
- Conditions
- Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
- Trial name
- NCT01874353
- Testing
- Olaparib 300mg tablets
- Where
- 126 sites in United States, Australia and 15 more
- Volunteers
- 327 people
- Sponsor
- AstraZeneca
Precocious, Leuprolide Acetate
Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty
The purpose of this extension study is to determine if leuprolide acetate (11.25 mg and 30 mg) is safe in treating children with Central Precocious Puberty over a longer period of time (36 months).
- Conditions
- Precocious, Leuprolide Acetate, Luteinizing Hormone (LH), Gonadotrophin-releasing Hormone Agonist (GnRHa)
- Trial name
- NCT00667446
- Testing
- Leuprolide Acetate 3 Month Depot
- Where
- 20 sites in United States, Puerto Rico
- Volunteers
- 72 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Diabetes Mellitus, Type 2, Noninsulin-Dependent Diabetes Mellitus
Effect of Duodenal Mucosal Resurfacing (DMR) Using the Revita System in the Treatment of Type 2 Diabetes (T2D)
The purpose of this study is to demonstrate the efficacy and safety of the Fractyl duodenal mucosal resurfacing (DMR) Procedure using the Revita System compared to a sham procedure for the treatment of uncontrolled type 2…
- Trial name
- NCT02879383
- Testing
- DMR Procedure
- Where
- 11 sites in Belgium, Brazil and 3 more
- Volunteers
- 109 people
- Sponsor
- Fractyl Health Inc.
Type 2 Diabetes Mellitus
Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus Glimepiride
This study will evaluate the efficacy and safety of vildagliptin 50 mg bid as add-on therapy to metformin plus glimepiride in patients with Type 2 Diabetes (T2D).
- Trial name
- Vildagliptin (NCT01233622)
- Testing
- Vildagliptin
- Where
- 55 sites in Australia, Germany and 7 more
- Volunteers
- 317 people
- Sponsor
- Novartis
Diabetes Mellitus, Non-Insulin-Dependent
MK-1006 Single Dose Study in Japanese Type 2 Diabetes Patients (MK-1006-005)
A single rising dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of MK-1006 in Japanese participants with Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT00791661
- Testing
- MK-1006
- Volunteers
- 24 people
- Sponsor
- Merck Sharp & Dohme LLC
Adverse Drug Event, Effect of Drug
Research on Human Insulin rDNA Safety and Efficacy in Patients With Type 2 Diabetes Mellitus
Objective: To evaluate the safety and efficacy of Human Insulin rDNA (Insuget) in patients with Type II Diabetes Mellitus. Study Design: Open-label, prospective, observational, single arm, multi-center, post-marketing…
- Conditions
- Adverse Drug Event, Effect of Drug, Type 2 Diabetes Treated With Insulin
- Trial name
- RISE (NCT05161741)
- Testing
- Insulin
- Where
- Pakistan
- Volunteers
- 238 people
- Sponsor
- Getz Pharma
Insulin-like Growth Factor-1 Deficiency
rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency
IGF-1 (insulin-like growth factor-1) is a hormone that is normally produced in the body in response to another hormone called growth hormone. Growth Hormone is produced by a small gland at the base of the brain (the pituitary).
- Trial name
- NCT00572156
- Testing
- NutropinAq® (Somatropin [rDNA origin]), Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Ipsen
Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
The purpose of this study is to: evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324 evaluate the efficacy, safety, tolerability, PK…
- Trial name
- NCT06845202
- Testing
- ALN-4324
- Where
- 22 sites in United States, Argentina and 4 more
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Diabetes Mellitus
Paediatric Use of the Abbott Sensor Based Glucose Monitoring System
Accuracy evaluation of the Abbott Sensor Based Glucose Monitoring System when used by children with diabetes.
- Trial name
- PUGS (NCT03433573)
- Testing
- Abbott Sensor Based Glucose Monitoring System
- Where
- 11 sites in United Kingdom
- Volunteers
- 103 people
- Sponsor
- Abbott Diabetes Care
Diabetes Mellitus
Study of a Novel Non-invasive Glucose Monitoring Device
This explorative clinical study has been launched to collect spectral Raman data paired with validated glucose reference values in diabetic patients.
- Trial name
- NCT03782441
- Testing
- Prototype 0.5
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- RSP Systems A/S
Ovarian Cancer Recurrent
DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer
The purpose of this trial is to investigate if maintenance DCVAC/OvCa after second-line chemotherapy of carboplatin/gemcitabine or carboplatin/paclitaxel improves efficacy outcomes in women with FIGO stage III and IV epithelial…
- Trial name
- NCT03657966
- Testing
- DCVAC/OvCa, Standard of Care Chemotherapy
- Where
- 8 sites in Czechia
- Volunteers
- 33 people
- Sponsor
- SOTIO a.s.
Diabetes, Diabetes Mellitus, Type 1
A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes
This trial is conducted in the United States of America (USA). The aim of the trial is to evaluate continuous subcutaneous infusion of NN1218 formulations and NovoLog® in subjects with type 1 diabetes.
- Trial name
- NCT01682902
- Testing
- Faster-acting insulin aspart, insulin aspart
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Novo Nordisk A/S
Lung Cancer (Diagnosis), Liver Cancer, Adult
A Study Evaluating a New Radiation Treatment Workflow (NGDS)
The purpose of this research is to evaluate the "Next Generation Delivery System" (NGDS) and determine if this machine will be more efficient at delivering radiation in shorter treatment time and better patient tolerance, with…
- Conditions
- Lung Cancer (Diagnosis), Liver Cancer, Adult, Pancreatic Cancer, Thoracic Cancers
- Trial name
- SPEED (NCT07824583)
- Testing
- Next Generation Delivery System (NGDS)
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Varian, a Siemens Healthineers Company
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes
This trial is conducted in Japan. This is a clinical trial to study the efficacy and safety of thrice daily Insulin Aspart compared to Glibenclamide in type 2 diabetic patients.
- Trial name
- NCT00267683
- Testing
- insulin aspart, glibenclamide
- Volunteers
- 9 people
- Sponsor
- Novo Nordisk A/S
Foot Ulcer, Diabetic
NuShield/Affinity for the Treatment of Neuropathic Diabetic Foot Ulcers
This study was designed to determine the heal rate of diabetic foot ulcers at 4 weeks, and complete closure at 8 and 12 weeks of patients treated with either NuShield or Affinity compared to standard care alone.
- Trial name
- NCT02461641
- Testing
- NuShield, Affinity, Standard of Care
- Where
- 7 sites in United States
- Volunteers
- 96 people
- Sponsor
- NuTech Medical, Inc
Secondary Hyperparathyroidism, End-stage Kidney Disease (ESKD)
Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1
This study is to evaluate the efficacy and safety of PLS240 in patients with hemodialysis-dependent end stage kidney disease (ESKD) and secondary hyperparathyroidism (SHPT). The study consists of two phases.
- Trial name
- PATH-1 (NCT05832931)
- Testing
- PLS240, Open-Label Extension PLS240
- Where
- 68 sites in United States, Bulgaria and 4 more
- Volunteers
- 362 people
- Sponsor
- Pathalys Pharma
Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors
RATIONALE: Erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00033241
- Testing
- erlotinib hydrochloride, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Sponsor
- OSI Pharmaceuticals
Diabetes, Healthy
Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH
The trial is conducted in Europe. The aim of the trial is to investigate if there is any drug to drug interaction between liraglutide and atorvastatin (Lipitor®), lisinopril (Zestril®), griseofulvin and digoxin (Lanoxin®).
- Trial name
- NCT01518166
- Testing
- liraglutide, atorvastatin, lisinopril
- Where
- Sweden
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro
Evaluation of post-prandial blood glucose excursions after a standardized meal and pre meal injections of individual doses of the study insulins.
- Trial name
- NCT01000922
- Testing
- Regular Human Insulin, Lispro, VIAject
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Biodel
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.